Evidence map›Paper›PMID 35782609›Full record

ArticleMolecular genetics and metabolism reports2022

Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3.

Ni-Chung Lee, Yin-Hsiu Chien, Chung-Hsing Wang, Siew-Lee Wong, Steven Shinn-Forng Peng, Fuu-Jen Tsai, Wuh-Liang Hwu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular genetics and metabolism reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Atypical case of neonatal-onset Gaucher disease type 3b: A case report.Molecular genetics and metabolism reports · 2025
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Ni-Chung LeeDepartment of Medical Genetics and Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Yin-Hsiu ChienDepartment of Medical Genetics and Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Chung-Hsing WangDivision of Genetics and Metabolism, Children's Hospital of China Medical University, Taichung, Taiwan.
Siew-Lee WongDepartment of Pediatrics, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan.
Steven Shinn-Forng PengDepartment of Radiology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Fuu-Jen TsaiDepartment of Medical Genetics, Children's Hospital, China Medical University, Taichung, Taiwan.
Wuh-Liang HwuDepartment of Medical Genetics and Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
National Taiwan University Hospital · TWNational Yang Ming Chiao Tung University · TWChia-Yi Christian Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with Gaucher disease type 3 (GD3), especially those with

Indexed as

AEs, Adverse eventsEliglustatERT, Enzyme replacement therapyGaucher diseaseGD, Gaucher diseaseLAPs, LymphadenopathiesSRT, Substrate reduction therapySubstrate reduction therapy

Identifiers

PMID35782609
PMCPMC9248212
OpenAlexW4224293451

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.